United States Sexually Transmitted Disease (STD) Testing Market, By Disease Type (Chlamydia, Gonorrhea, Genital Herpes, Syphilis, Human Immunodeficiency Virus (HIV), Human papillomavirus (HPV)); By Product Type (Instruments, Reagents & Kits); By Device Ty

Saudi Arabia Furniture Market, By Product (Beds, Tables & Desks, Sofa & Couch, Chairs & Stools, Cabinets & Shelves); By Application (Residential, Commercial); By Material (Metal, Wood, Plastic, Glass), Trend Analysis, Competitive Landscape & Forecast, 2019–2029

United States Sexually Transmitted Disease (STD) Testing Market Size Grows at Significant CAGR of 8.6% to Touch USD 6.47 Billion by 2029

United States sexually transmitted disease (STD) testing market is flourishing because of the growing prevalence of STDs and increasing awareness about STDs and the importance of testing for treating them.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the United States sexually transmitted disease (STD) testing market size at USD 3.62 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the United States sexually transmitted disease (STD) testing market size to grow at a significant CAGR of 8.6% reaching a value of USD 6.47 billion by 2029. Major growth drivers for the United States sexually transmitted disease (STD) testing market include increasing awareness, changing sexual behaviors, and growing instances of sexually transmitted infections (STIs) among young adults. On March 16, 2023, CDC data revealed a resurgence of STDs, with 2.5 million cases reported in 2021, a 4.4% increase in chlamydia, gonorrhea, syphilis, and congenital syphilis cases. Notably, syphilis cases among women rose by 49%, and congenital syphilis increased by 24% compared to 2020. STDs can result from various forms of intimate contact and are caused by bacteria, pathogens, or parasites, with transmission even possible through breastfeeding, childbirth, and needle-sharing. Advances in diagnostic technology and treatment, along with educational programs and government initiatives, are driving market growth, with a growing demand for point-of-care testing and sophisticated products. However, cost of testing and stigma associated with STDs are anticipated to restrain the overall market growth during the period in analysis.

United States Sexually Transmitted Disease (STD) Testing Market – Overview

The United States Sexually Transmitted Disease (STD) testing market refers to the sector of the healthcare industry in the United States focused on the testing, diagnosis, and screening of individuals for sexually transmitted diseases (STDs). This market encompasses a wide range of testing methods, diagnostic tools, and services aimed at identifying and monitoring the presence of various STDs, including but not limited to chlamydia, gonorrhea, syphilis, HIV, herpes, and HPV. It involves both public and private healthcare providers, laboratories, and facilities that offer STD testing services, and it is influenced by awareness, government initiatives, technological advancements, and changes in sexual behavior. The market seeks to address the prevention, early detection, and treatment of STDs to mitigate their impact on public health.

Impact of COVID-19 on United States Sexually Transmitted Disease (STD) Testing Market

COVID-19 pandemic adversely affected the United States sexually transmitted disease (STD) testing market. This impact was mainly due to a reduction in STD testing rates, leading to a substantial increase in unreported cases and the potential for heightened disease transmission. In FY2020, prominent market players faced challenges, witnessing a decline in their segmental revenue growth, primarily as a consequence of the novel COVID-19 pandemic. The combination of reduced testing and the broader economic repercussions of the pandemic underscored the vulnerability of the STD testing market during times of public health crises.

United States Sexually Transmitted Disease (STD) Testing Market – By Disease Type

Based on disease type, the United States sexually transmitted disease (STD) testing market is divided into Chlamydia, Gonorrhea, Genital Herpes, Syphilis, Human Immunodeficiency Virus (HIV), and Human papillomavirus (HPV) segments. The chlamydia segment holds the highest share in the United States sexually transmitted disease (STD) market by disease type. Chlamydia is one of the most common STDs in the country, contributing to its significant prevalence. Routine screening programs and awareness campaigns have also driven increased testing for chlamydia. Additionally, the disease is often asymptomatic, making regular testing vital for early detection. With its relatively high incidence and the focus on prevention and early diagnosis, the chlamydia segment is poised to maintain its leading position during the forecast period in the United States STD market.

Competitive Landscape

Major players operating in the United States sexually transmitted disease (STD) testing market include Abbott, bioMerieux Inc., Bio Rad Laboratories Inc., DiaSorin S.p.A, Cepheid (Danaher), Hologic, Inc., F. Hoffmann-La Roche Ltd, BD, and Thermo Fisher Scientific Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of United States Sexually Transmitted Disease (STD) Testing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in United States Sexually Transmitted Disease (STD) Testing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.